GKOS vs. IDXX: Glaukos vs. IDEXX Laboratories Stock Comparison

Company Profile

Glaukos (GKOS) and IDEXX Laboratories (IDXX) are both classified in the Health Care Equipment sub-industry within the broader Health Care Equipment & Supplies industry, placing them in the closest GICS peer bucket.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

IDEXX Laboratories (IDXX) has an aggressive beta of 1.44, indicating higher sensitivity to broad-market moves, while Glaukos (GKOS) is defensive at 0.68 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Glaukos (GKOS) reports a negative ROE of -22.84%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile IDEXX Laboratories (IDXX) reports 68.93%, ranking against industry peers normally.

Glaukos (GKOS) reports a negative net margin of -24.60%, usually indicating a net loss over the period. Meanwhile IDEXX Laboratories (IDXX) reports 25.36%, ranking against industry peers normally.

IDEXX Laboratories (IDXX) at 33.14% operates in the top operating margin quartile, ahead of Glaukos (GKOS) at 0.39%, which runs around its industry’s norm.

Profitability Metrics

Growth

Glaukos (GKOS) at 32.33% sits in the top revenue growth quartile, while IDEXX Laboratories (IDXX) at 10.42% is closer to the peer norm — faster top-line expansion for GKOS.

Only one side can be read here: IDEXX Laboratories (IDXX) reports EPS growth of 22.59%, ranked against its industry; Glaukos (GKOS) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Glaukos (GKOS) at 4.57 carries current ratio above its industry’s typical mid-range, while IDEXX Laboratories (IDXX) at 1.19 runs in the tighter-liquidity quartile — different working-capital profiles, both worth examining.

Glaukos (GKOS) at 0.15 keeps leverage in the lower industry quartile, while IDEXX Laboratories (IDXX) at 0.52 runs a more typical debt-to-equity mix.

Financial Strength Metrics

Dividends

Neither Glaukos (GKOS) nor IDEXX Laboratories (IDXX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Glaukos (GKOS) nor IDEXX Laboratories (IDXX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: IDEXX Laboratories (IDXX) trades at 45.56 times trailing earnings, ranked against its peers, while Glaukos (GKOS) has no P/E ratio this period.

Investors are paying well above the peer range per dollar of sales for both Glaukos (GKOS) at 19.24 and IDEXX Laboratories (IDXX) at 11.42 — each P/S ratio clears its industry’s benchmark range.

Measured against book value, both Glaukos (GKOS) at 18.51 and IDEXX Laboratories (IDXX) at 28.50 look expensive — each P/B ratio sits above its industry’s benchmark range.

Valuation Metrics